Published in Br J Haematol on January 01, 2003
Lack of Muc1-regulated beta-catenin stability results in aberrant expansion of CD11b+Gr1+ myeloid-derived suppressor cells from the bone marrow. Cancer Res (2009) 0.91
Serum cancer antigen 15-3 concentrations in patients with sickle cell disease. Br J Haematol (2006) 0.81
Downregulation of hematopoietic MUC1 during experimental colitis increases tumor-promoting myeloid-derived suppressor cells. Clin Cancer Res (2013) 0.77
Spurious laboratory alterations in pernicious anemia. Rev Bras Hematol Hemoter (2015) 0.75
From the Cradle to the Grave: The Role of Macrophages in Erythropoiesis and Erythrophagocytosis. Front Immunol (2017) 0.75
Identification and expansion of human colon-cancer-initiating cells. Nature (2006) 24.44
Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ Res (2004) 8.41
Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature (2010) 6.13
The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med (2008) 5.74
The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res (2008) 3.21
Treatment of sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): report of a case and literature review. Am J Hematol (2002) 2.48
Mobilization of bone marrow-derived stem cells after myocardial infarction and left ventricular function. Eur Heart J (2005) 2.33
Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. Blood (2007) 2.03
A three-step pathway comprising PLZF/miR-146a/CXCR4 controls megakaryopoiesis. Nat Cell Biol (2008) 1.97
Clinico-pathological characteristics of myeloid sarcoma at diagnosis and during follow-up: report of 12 cases from a single institution. Leuk Res (2004) 1.84
Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. J Nucl Med (2006) 1.83
Human MRE11 is inactivated in mismatch repair-deficient cancers. EMBO Rep (2002) 1.80
Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients. J Clin Oncol (2003) 1.73
Hedgehog controls neural stem cells through p53-independent regulation of Nanog. EMBO J (2010) 1.73
Guanine nucleotide depletion triggers cell cycle arrest and apoptosis in human neuroblastoma cell lines. Int J Cancer (2004) 1.68
Isolation and characterization of CD146+ multipotent mesenchymal stromal cells. Exp Hematol (2008) 1.68
Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK- cell lysis. Blood (2007) 1.63
Characterization and intracellular localization of the Epstein-Barr virus protein BFLF2: interactions with BFRF1 and with the nuclear lamina. J Virol (2005) 1.62
Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. Blood (2006) 1.60
BFRF1 of Epstein-Barr virus is essential for efficient primary viral envelopment and egress. J Virol (2005) 1.59
Role for granulocyte colony-stimulating factor in the generation of human T regulatory type 1 cells. Blood (2002) 1.57
Aspirin extrusion from human platelets through multidrug resistance protein-4-mediated transport: evidence of a reduced drug action in patients after coronary artery bypass grafting. J Am Coll Cardiol (2011) 1.55
Combined expression of pTalpha and Notch3 in T cell leukemia identifies the requirement of preTCR for leukemogenesis. Proc Natl Acad Sci U S A (2002) 1.54
Mutations of an intronic repeat induce impaired MRE11 expression in primary human cancer with microsatellite instability. Oncogene (2004) 1.46
Comment on: isolation and characterization of tumorigenic extrahepatic cholangiocarcinoma cells with stem cell-like properties. Int J Cancer (2011) 1.44
Prognostic significance of reverse transcriptase-polymerase chain reaction-negative sentinel nodes in malignant melanoma. Ann Surg Oncol (2003) 1.42
Functional properties of cells obtained from human cord blood CD34+ stem cells and mouse cardiac myocytes in coculture. Am J Physiol Heart Circ Physiol (2008) 1.42
Identification of the hemangioblast in postnatal life. Blood (2002) 1.42
Semiquantitative RT-PCR analysis to assess the expression levels of multiple transcripts from the same sample. Biol Proced Online (2001) 1.40
MicroRNA 223-dependent expression of LMO2 regulates normal erythropoiesis. Haematologica (2009) 1.40
A policy for the disposal of autologous hematopoietic progenitor cells: report from an Italian consensus panel. Transfusion (2014) 1.38
Notch3 and pre-TCR interaction unveils distinct NF-kappaB pathways in T-cell development and leukemia. EMBO J (2006) 1.37
Ligand-regulated association of ErbB-4 to the transcriptional co-activator YAP65 controls transcription at the nuclear level. Exp Cell Res (2004) 1.35
Myoendothelial differentiation of human umbilical cord blood-derived stem cells in ischemic limb tissues. Circ Res (2003) 1.32
Genome-wide significance for a modifier of age at neurological onset in Huntington's disease at 6q23-24: the HD MAPS study. BMC Med Genet (2006) 1.30
Granulocyte colony-stimulating factor promotes the generation of regulatory DC through induction of IL-10 and IFN-alpha. Eur J Immunol (2004) 1.29
Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins. Am J Pathol (2003) 1.27
Transplantation of low dose CD34+KDR+ cells promotes vascular and muscular regeneration in ischemic limbs. FASEB J (2004) 1.27
Targeting CD133 antigen in cancer. Expert Opin Ther Targets (2009) 1.26
Tumor-associated Tn-MUC1 glycoform is internalized through the macrophage galactose-type C-type lectin and delivered to the HLA class I and II compartments in dendritic cells. Cancer Res (2007) 1.26
HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumour Biol (2010) 1.24
The convergence of radiation and immunogenic cell death signaling pathways. Front Oncol (2012) 1.24
Caveolin-1 tumor-promoting role in human melanoma. Int J Cancer (2009) 1.23
Endogenous G-CSF and CD34+ cell mobilization after acute myocardial infarction. Int J Cardiol (2005) 1.23
Subcellular localization of the BRCA1 gene product in mitotic cells. Genes Chromosomes Cancer (2002) 1.22
MicroRNA 155 modulates megakaryopoiesis at progenitor and precursor level by targeting Ets-1 and Meis1 transcription factors. Br J Haematol (2008) 1.22
Notch3 and the Notch3-upregulated RNA-binding protein HuD regulate Ikaros alternative splicing. EMBO J (2007) 1.20
The E3 ligase Aip4/Itch ubiquitinates and targets ErbB-4 for degradation. FASEB J (2007) 1.19
Pre-TCR-triggered ERK signalling-dependent downregulation of E2A activity in Notch3-induced T-cell lymphoma. EMBO Rep (2003) 1.18
retSDR1, a short-chain retinol dehydrogenase/reductase, is retinoic acid-inducible and frequently deleted in human neuroblastoma cell lines. Cancer Res (2002) 1.17
Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors. Clin Cancer Res (2009) 1.17
p38 MAPK activation controls the TLR3-mediated up-regulation of cytotoxicity and cytokine production in human NK cells. Blood (2004) 1.14
Suppression of dendritic cell differentiation through cytokines released by Primary Effusion Lymphoma cells. Immunol Lett (2008) 1.10
miR-126&126* restored expressions play a tumor suppressor role by directly regulating ADAM9 and MMP7 in melanoma. PLoS One (2013) 1.10
Celecoxib induces MRP-4 in lung cancer cells: therapeutic implications. J Clin Oncol (2007) 1.10
SH2-containing inositol phosphatase (SHIP-1) transiently translocates to raft domains and modulates CD16-mediated cytotoxicity in human NK cells. Blood (2002) 1.09
Expression of activated Notch3 in transgenic mice enhances generation of T regulatory cells and protects against experimental autoimmune diabetes. J Immunol (2003) 1.09
Inhibition of cell growth by EGR-1 in human primary cultures from malignant glioma. Cancer Cell Int (2004) 1.08
Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis. Cancer (2010) 1.07
Primary effusion lymphoma cell death induced by bortezomib and AG 490 activates dendritic cells through CD91. PLoS One (2012) 1.07
Distinct brain volume changes correlating with clinical stage, disease progression rate, mutation size, and age at onset prediction as early biomarkers of brain atrophy in Huntington's disease. CNS Neurosci Ther (2009) 1.06
EGF- and cell-cycle-regulated STAG1/PMEPA1/ERG1.2 belongs to a conserved gene family and is overexpressed and amplified in breast and ovarian cancer. Mol Carcinog (2003) 1.06
PKC theta mediates pre-TCR signaling and contributes to Notch3-induced T-cell leukemia. Oncogene (2005) 1.06
Multiple members of the TNF superfamily contribute to IFN-gamma-mediated inhibition of erythropoiesis. J Immunol (2005) 1.05
Chemosensitivity profile assay of circulating cancer cells: prognostic and predictive value in epithelial tumors. Int J Cancer (2010) 1.05
NFI-A directs the fate of hematopoietic progenitors to the erythroid or granulocytic lineage and controls beta-globin and G-CSF receptor expression. Blood (2009) 1.05
ARS Component B: structural characterization, tissue expression and regulation of the gene and protein (SLURP-1) associated with Mal de Meleda. Eur J Dermatol (2004) 1.05
Activation of Syk tyrosine kinase is required for c-Cbl-mediated ubiquitination of Fcepsilon RI and Syk in RBL cells. J Biol Chem (2002) 1.05
Vaginoplasty using autologous in vitro cultured vaginal tissue in a patient with Mayer-von-Rokitansky-Kuster-Hauser syndrome. Hum Reprod (2007) 1.04
REN: a novel, developmentally regulated gene that promotes neural cell differentiation. J Cell Biol (2002) 1.03
Constitutively active Notch1 induces growth arrest of HPV-positive cervical cancer cells via separate signaling pathways. Exp Cell Res (2005) 1.03
Podocalyxin is expressed in normal and leukemic monocytes. Blood Cells Mol Dis (2006) 1.03
Proline-rich tyrosine kinase 2 and Rac activation by chemokine and integrin receptors controls NK cell transendothelial migration. J Immunol (2003) 1.02
Current approach in the treatment of hepatocellular carcinoma. World J Gastrointest Oncol (2010) 1.01
Proliferation state and polo-like kinase1 dependence of tumorigenic colon cancer cells. Stem Cells (2012) 1.00
Targeting of macrophage galactose-type C-type lectin (MGL) induces DC signaling and activation. Eur J Immunol (2012) 0.99
Notch3 and canonical NF-kappaB signaling pathways cooperatively regulate Foxp3 transcription. J Immunol (2011) 0.99
MAGE-A and NY-ESO-1 expression in cervical cancer: prognostic factors and effects of chemotherapy. Am J Obstet Gynecol (2008) 0.99
Ovarian tumor marker HE4 is differently expressed during the phases of the menstrual cycle in healthy young women. Tumour Biol (2010) 0.99
New models for cancer research: human cancer stem cell xenografts. Curr Opin Pharmacol (2010) 0.99
Arf6: a new player in FcgammaRIIIA lymphocyte-mediated cytotoxicity. Blood (2005) 0.98
Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome. Blood (2012) 0.98
Transferrin receptor 2 is frequently expressed in human cancer cell lines. Blood Cells Mol Dis (2007) 0.98
Human adipose-derived stromal cells for cell-based therapies in the treatment of systemic sclerosis. Cell Transplant (2013) 0.98
UDP-glucuronosyltransferases 1A expression in human urinary bladder and colon cancer by immunohistochemistry. Oncol Rep (2005) 0.98
Role of HE4, CA72.4, and CA125 in monitoring ovarian cancer. Tumour Biol (2012) 0.98
p16/Ki-67 dual staining in cervico-vaginal cytology: correlation with histology, Human Papillomavirus detection and genotyping in women undergoing colposcopy. Gynecol Oncol (2012) 0.98
Genotype-dependent priming to self- and xeno-cannibalism in heterozygous and homozygous lymphoblasts from patients with Huntington's disease. J Neurochem (2006) 0.97
Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis. Apoptosis (2007) 0.97